Lage Hermann
Fachbereich Pathologie, Vivantes Klinikum Neukölln, Rudower Allee 48, 12351, Berlin, Germany.
Recent Results Cancer Res. 2016;209:87-94. doi: 10.1007/978-3-319-42934-2_6.
Multidrug resistance (MDR) to pharmaceutical active agents is a common clinical problem in patients suffering from cancer. MDR is often mediated by over expression of trans-membrane xenobiotic transport molecules belonging to the superfamily of ATP-binding cassette (ABC)-transporters. This protein family includes the classical MDR-associated transporter ABCB1 (MDR1/P-gp). Inhibition of ABC-transporters by low molecular weight compounds in cancer patients has been extensively investigated in clinical trials, but the results have been disappointing. Thus, in the last decades alternative experimental therapeutic strategies for overcoming MDR were under extensive investigation. These include gene therapeutic approaches applying antisense-, ribozyme-, RNA interference-, and CRISPR/Cas9-based techniques. Various delivery strategies were used to reverse MDR in different tumor models in vitro and in vivo. Results and conclusions of these gene therapeutic studies will be discussed.
对药物活性剂的多药耐药性(MDR)是癌症患者中常见的临床问题。MDR通常由属于ATP结合盒(ABC)转运蛋白超家族的跨膜异生物质转运分子的过表达介导。该蛋白家族包括经典的MDR相关转运蛋白ABCB1(MDR1/P-gp)。在癌症患者中,低分子量化合物对ABC转运蛋白的抑制作用已在临床试验中进行了广泛研究,但结果令人失望。因此,在过去几十年中,克服MDR的替代实验治疗策略受到了广泛研究。这些策略包括应用反义、核酶、RNA干扰和基于CRISPR/Cas9技术的基因治疗方法。在体外和体内的不同肿瘤模型中,使用了各种递送策略来逆转MDR。将讨论这些基因治疗研究的结果和结论。